{"id":1833,"date":"2026-11-18T10:57:25","date_gmt":"2026-11-18T09:57:25","guid":{"rendered":"https:\/\/pharmaceuticalinnovation.es\/?p=1833"},"modified":"2026-11-18T10:57:26","modified_gmt":"2026-11-18T09:57:26","slug":"sft-1-eu-orphan-drug-designation","status":"publish","type":"post","link":"https:\/\/pharmaceuticalinnovation.es\/es\/sft-1-eu-orphan-drug-designation\/","title":{"rendered":"Rimonabant (SFT-1) receives EU orphan medicinal product designation for spinal cord injury"},"content":{"rendered":"<p class=\"wp-block-paragraph\">El <strong>European Commission<\/strong>, by Implementing Decision C (2026) 7475 of 19 October 2026, has designated <strong>rimonabant, the active substance in SFT-1, as an orphan medicinal product for the treatment of spinal cord injuries<\/strong> (Community register EU\/3\/26\/3289). At Pharmaceutical Innovation Services, we are delighted to celebrate this important milestone for Sinfatin S.L.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">A new step in the development of SFT-1<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Spinal cord injury is a complex and rare neurological condition that can profoundly affect the mobility, independence and quality of life of those affected. The SFT-1 clinical programme aims to improve walking ability in people with spinal cord injury who retain the ability to walk.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SFT-1 contains low-dose rimonabant (5 mg), a cannabinoid CB1 receptor antagonist\/inverse agonist that acts on the central nervous system. Results obtained to date, including those from the Phase 2b RIMOFATSCI-2 trial, point to its potential to improve motor function in people with incomplete thoracolumbar spinal cord injury.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>The orphan medicinal product designation marks the beginning of a new stage in progressing towards a potential therapeutic alternative in an area of unmet medical need<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Our contribution<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Pharmaceutical Innovation Services is a partner of Sinfatin and has been involved in the development of SFT-1 from the outset, including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>development of the active substance synthesis process;<\/li>\n\n\n\n<li>development of the finished product in various doses and pharmaceutical forms;<\/li>\n\n\n\n<li>regulatory strategy and documentation.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">A shared milestone<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">We congratulate the Sinfatin team and the centres and organisations that have contributed to this achievement: Hospital Nacional de Parapl\u00e9jicos de Toledo and its Foundation, Institut Guttmann, BIC Gipuzkoa, Medalchemy, Tecnalia, Laboratorium Sanitatis, CIDETEC and Fundaci\u00f3n Te\u00f3filo Hernando.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>En<\/strong> <a href=\"https:\/\/pharmaceuticalinnovation.es\/es\/innovacion-en-el-desarrollo-de-farmacos\/\" target=\"_blank\" rel=\"noopener\"><strong>Servicios de Innovaci\u00f3n Farmac\u00e9utica<\/strong><\/a><strong>, we reaffirm our commitment to continuing our collaboration with Sinfatin to advance its projects and achieve new milestones together.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Would you like to learn more about SFT-1 and its clinical development? Find all the details on the <a href=\"https:\/\/sinfatin.com\/\" target=\"_blank\" rel=\"noopener\">Sinfatin website<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>The European Commission, by Implementing Decision C (2026) 7475 of 19 October 2026, has designated rimonabant, the active substance in SFT-1, as an orphan medicinal product for the treatment of spinal cord injuries (Community register EU\/3\/26\/3289). At Pharmaceutical Innovation Services, we are delighted to celebrate this important milestone for Sinfatin S.L. A new step in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1834,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-1833","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/pharmaceuticalinnovation.es\/es\/wp-json\/wp\/v2\/posts\/1833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharmaceuticalinnovation.es\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaceuticalinnovation.es\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaceuticalinnovation.es\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaceuticalinnovation.es\/es\/wp-json\/wp\/v2\/comments?post=1833"}],"version-history":[{"count":1,"href":"https:\/\/pharmaceuticalinnovation.es\/es\/wp-json\/wp\/v2\/posts\/1833\/revisions"}],"predecessor-version":[{"id":1835,"href":"https:\/\/pharmaceuticalinnovation.es\/es\/wp-json\/wp\/v2\/posts\/1833\/revisions\/1835"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaceuticalinnovation.es\/es\/wp-json\/wp\/v2\/media\/1834"}],"wp:attachment":[{"href":"https:\/\/pharmaceuticalinnovation.es\/es\/wp-json\/wp\/v2\/media?parent=1833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaceuticalinnovation.es\/es\/wp-json\/wp\/v2\/categories?post=1833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaceuticalinnovation.es\/es\/wp-json\/wp\/v2\/tags?post=1833"}],"curies":[{"name":"Gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}